Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer (IXAMPLE2)
This study is ongoing, but not recruiting participants.
Study NCT00883116   Information provided by Bristol-Myers Squibb

First Received on April 16, 2009.   Last Updated on March 28, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Endometrial Cancer
Additional conditions recognized in this trial
Adenoma
Endometrial Neoplasms
Sarcoma, Endometrial Stromal
More general conditions related to this trial
Endometrial Stromal Tumors
Genital Diseases, Female
Genital Neoplasms, Female
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Complex and Mixed
Neoplasms, Connective and Soft Tissue
Neoplasms, Glandular and Epithelial
Sarcoma
Urogenital Neoplasms
Uterine Diseases
Uterine Neoplasms
Interventions listed in this trial
Ixabepilone
Doxorubicin
Paclitaxel
Additional drug interventions recognized in this trial
Epothilones
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Bristol-Myers Squibb


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services